Clinical trial · Interventional
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GW786034 | Drug | Pazopanib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluate the safety and tolerability of GW786034 in patients with relapsed or refractory multiple myeloma (MM).
Secondary outcomes (1)
- measure
- Evaluate time-to-tumor progression (TTP), time to response, and duration of response. Characterize the pharmacokinetics of GW786034 in patients with MM.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion criteria: * Must have diagnosis of relapsed or refractory multiple. * bone marrow function \[ANC (absolute neutrophil count) greater than 1000/mm3\]; platelet count greater than or equal to 75,000/mm3. * renal function (calculated creatinine clearance \>50 mL.min, albumin less than or equal to 500 mg). Exclusion criteria: * Failed more than 3 prior lines of therapy including stem cell transplant. * Females who are pregnant or nursing. * Unstable blood pressure. * Significant heart conditions or history of thrombosis. * Any unstable, pre-existing major medical condition or history of other cancers. * Have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.
References
Publications (1)
- BACKGROUNDPrince HM, Honemann D, Spencer A, Rizzieri DA, Stadtmauer EA, Roberts AW, Bahlis N, Tricot G, Bell B, Demarini DJ, Benjamin Suttle A, Baker KL, Pandite LN. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood. 2009 May 7;113(19):4819-20. doi: 10.1182/blood-2009-02-207209. No abstract available. PMID 19423744